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Alkaline hydrolysis of mouse-adapted scrapie for inactivation
and disposal of prion-positive material1
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P. B. Nash,‡ G. C. Smith,* and K. E. Belk*3
*Center for Meat Safety and Quality, Department of Animal Sciences, Colorado State University, Fort Collins,
CO 80523; †Veterinary Diagnostics Laboratory, Colorado State University, Fort Collins, CO 80523;
and ‡USDA-APHIS-WS-National Wildlife Research Center, Fort Collins, CO 80521

ABSTRACT: Prion diseases such as bovine spongiform encephalopathy, chronic wasting disease, and
scrapie pose serious risks to human and animal health
due to a host of disease-specific factors, including the
resistance of infectious prions (PrPSc) to natural degradation and to most commercial inactivation procedures.
In an attempt to address this concern, a mouse model
was used to compare the efficacy of an alkaline hydrolysis process with a simulated continuous-flow rendering treatment for disposal of PrPSc-infected biological
material. Female C57/BL6 mice (N = 120) were randomly divided into 4 treatment groups (n = 30), and
each mouse was injected intraperitoneally with their
designated treatment inoculum. Treatment groups
1 and 2 served as the positive and negative controls,
respectively. Group 3 was inoculated with rendered
scrapie-positive mouse brain material to investigate
the effectiveness of simulated continuous-flow rendering practices to reduce or eliminate PrPSc. Group 4
was inoculated with hydrolyzed scrapie-positive mouse
brain material to determine the sterilizing effect of alkaline hydrolysis on PrPSc. Mice were monitored for

overt signs of disease, and those showing clinical signs
were killed to prevent undue suffering. Brains were obtained from all mice that died (or were killed) and analyzed with an ELISA for the presence of PrPSc. Results
indicated that the simulated continuous-flow rendering
treatment used for preparing the rendering treatment
group inoculum failed to completely eliminate PrPSc.
Rendering delayed, but did not stop, clinical mouseadapted scrapie transmission. Compared with positive
controls, the rendering treatment group experienced an
approximate 45-d average delay in days to death (250
vs. 205 d for positive controls; P < 0.0001) and a death
loss of 73.9% (P = 0.0094). Positive controls suffered
100% death loss. The results validated the efficacy of
the alkaline hydrolysis treatment to inactivate all PrPSc
because no alkaline hydrolysis treatment group mice
succumbed to the disease (P < 0.0001). Based on our
results, alkaline hydrolysis should be considered by the
animal rendering and beef packing industries as an alternative to incineration, landfill burial, and rendering
for disposing of biological material potentially infected
or contaminated with prion disease.
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INTRODUCTION
After the discovery of bovine spongiform encephalopathy (BSE) in the United States, the Food and Drug
Administration (FDA) published a proposed rule in
the Federal Register in October 2005 that would prohibit certain cattle-derived materials from being included in the food and feed of all animals. The Final
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Rule of the FDA was published on April 25, 2008 and
will take effect on April 27, 2009 (DHHS-FDA, 2008).
Under the enhanced feed regulations, the list of prohibited materials includes the entire carcass of BSEpositive cattle, the brains and spinal cords from cattle
30 mo of age and older, and “the entire carcass of cattle not inspected and passed for human consumption
that are 30 mo of age or older from which brains and
spinal cords were not removed” (among other identified materials; DHHS-FDA, 2008). Using USDA-NASS
(2008a,b) production and population statistics as well
as the estimate reported by Roeber et al. (2001) for the
percentage of nonambulatory disabled cattle offered for
slaughter, the proposed rule of the FDA would prohibit the heads (including the brain) and spinal cords
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from the 6.23 million cows and bulls slaughtered; the
entire carcass of approximately 1.86 million on-farm
cattle mortalities; the entire carcass of approximately
49,800 nonambulatory cows and bulls condemned at
antemortem inspection; all inedible offal products from
noninspected slaughter facilities (150,000 cattle); and
the heads (including the brain) and spinal cords from
the small proportion of fed steers and heifers that are
identified as being 30 mo of age and older from entering
the animal feed system.
As a consequence of the new feed regulations, those
cattle-derived materials prohibited from use in animal
feeds will need to be disposed of by means other than
rendering. Alkaline hydrolysis may have potential as an
alternative to rendering for disposing of these potentially infectious tissues and animal carcasses. Therefore, the objective was to use a murine-based model to
compare the efficacy of an alkaline hydrolysis process
to a simulated continuous-flow rendering treatment for
disposal of biological material infected with mouseadapted scrapie.

MATERIALS AND METHODS
Animal procedures were approved by the Colorado
State University Animal Care and Use Committee and
the USDA-APHIS-Wildlife Services-National Wildlife
Research Center (NWRC) Institutional Animal Care
and Use Committee.

Treatment Group Inocula
A known mouse-adapted scrapie-positive (C57/BL6)
mouse brain (once passed from original mice obtained
from Rocky Mountain Laboratories, Hamilton, MT)
was removed from −70°C storage (Revco, Thermo
Electron Corporation, Asheville, NC) and homogenized
into a slurry with a sterilized scalpel blade. The mouse
brain homogenate was divided into 3 portions using
a scientific balance (Sartorius Microbalance, Sartorius Ltd., Epsom, United Kingdom) and each portion
(~0.110 g) was randomly assigned to the positive control, rendering, or alkaline hydrolysis treatment groups.
Homogenized treatment samples were placed in 200-µL
PCR tubes (Eppendorf North America, Westbury, NY)
and refrozen at −70°C until the next stage of the experiment. All treatment group inocula (including the
inoculum for the negative control treatment group)
were diluted after their respective treatments with 10%
(wt/vol) PBS (Difco, Becton, Dickinson and Company,
Franklin Lakes, NJ) to a final volume of 16 mL. The
final concentration of brain matter in the treatment
group inocula was 6.25 µg of brain matter per microliter.
Positive and Negative Control Treatment
Groups. One-third of the scrapie-positive mouse
brain homogenate was left untreated, transferred to a
Dounce tissue grinder (Kimble/Kontes, Vineland, NJ),
and ground further with a small volume of PBS. Af-

ter homogenization, the brain homogenate solution was
transferred to a sterile 50-mL centrifuge tube (Thermo
Fisher Scientific Inc., Waltham, MA), and additional
PBS was added to achieve a final volume of 16 mL.
This sample served as the inoculum for the positive
control treatment group.
The negative control treatment group mouse brain
(~0.100 g) originated from a known scrapie-negative
mouse that was used in a previous study and known to
never have been exposed to infectious prions (PrPSc).
The mouse brain homogenate was diluted with PBS to
achieve a final inoculum volume of 16 mL.
Rendering Treatment Group. The purpose of
the rendering treatment was to evaluate the efficacy
of simulated continuous-flow rendering to inactivate
PrPSc. The continuous cooker is an agitated vessel that
raises the temperature of raw material to 115 to 145°C
over a 45- to 90-min period, evaporating moisture, as
well as releasing fat from protein and bone for separation and recycling (Anderson, 2006). The continuous
cooker was modeled in our laboratory after consultation with D. Kirstein (director of technical services,
Darling International Inc., Des Moines, IA, personal
communication) and K. Kage (plant manager, Darling
International Inc., Denver, CO, personal communication). It was decided that a test tube apparatus, which
cooked the scrapie-positive mouse brain homogenate
in vegetable/animal shortening at a 2:1 shortening to
brain ratio, was acceptable for representing the physical conditions of continuous-flow rendering.
A 500-mL beaker containing 350 mL of shortening
(Great Value, Wal-Mart Stores Inc., Bentonville, AR)
was heated to 138°C and maintained between 120 and
138°C for the entire length of the rendering procedure.
The temperature of the shortening was monitored by
a suspended type-K thermocouple thermometer probe
(Temptec Accutuff 340, Atkins Technical Inc., Gainesville, FL) placed in the beaker. A test tube containing
shortening plus scrapie-positive mouse brain homogenate was suspended in the beaker of heated shortening and agitated periodically with a piece of steel
wire. The temperature of the contents in the test tube
was monitored by a suspended type-K thermocouple
(Omega Engineering Inc., Stamford, CT) attached to
a microprocessor thermometer (model HH21, Omega
Engineering Inc.). The temperature of the test tube
was monitored to ensure it did not exceed 135°C, and
the brain homogenate was cooked at this temperature
for 45 min.
After the test tube was removed from the apparatus
and allowed to cool, the rendered brain homogenate was
transferred to a freezer vial, mixed with 500 µL of PBS,
and frozen (−70°C). On the day of inoculation, the rendered mouse brain homogenate was removed from frozen storage, ground with a Dounce tissue grinder, and
diluted with 15.5 mL of PBS to create the rendering
treatment group inoculum.
Alkaline Hydrolysis Treatment Group. The
scrapie-positive mouse brain homogenate was removed
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from −70°C storage, thawed to ambient temperature,
and transferred to a 200-µL PCR tube. Potassium hydroxide and distilled water were added to the brain homogenate in accordance with the operating instructions
provided by the manufacturer of the alkaline hydrolysis
unit (K. Morris, owner and chief operating officer, Hydrol-Pro Technologies Inc., Zephyr Hills, FL, personal
communication). Technical grade KOH (50% wt/wt;
Univar USA Inc., Seattle, WA) was added to the PCR
tube until it reached 8% of the weight of the mouse
brain homogenate; distilled water was then added until
it reached 12% of the combined sample weight (KOH
plus brain homogenate). The PCR tube was placed inside a small stainless steel module, and the module was
sealed to prevent the possibility that brain material
could be expelled from it during the alkaline hydrolysis
process. The module was transported to the alkaline
hydrolysis unit (BioMEER, Hydrol-Pro Technologies
Inc., Zephyrhills, FL) located at the Colorado State
University James L. Voss Teaching Hospital Veterinary
Diagnostics Laboratory in Fort Collins. The stainless
steel module was fastened to the wastewater collection
rim just beneath the lid, the vessel was sealed, and the
alkaline hydrolysis process was initiated. The alkaline
hydrolysis vessel is designed to operate at a peak temperature of 150°C and at a pressure of approximately
4.14 bars (60 PSI). The unit used in this study is designed to hydrolyze 1,818 kg (4,000 lb) of biological
raw material (e.g., carcasses, necropsy samples, etc.)
per cycle, in addition to the volume of KOH and water required in the hydrolysis process. In addition to
the 9 to 12 h that is required to bring the vessel to
the desired temperature, the efficiency of the wastewater removal step is highly variable, which can extend
the hydrolysis procedure to 4 or 5 d. Once the vessel
reached its peak operating temperature (150°C), it was
maintained at this temperature until the wastewater
removal step was completed (weight of hydrolyzed material is reduced to approximately 50% of the starting
weight), at which time the effluent was discharged for
disposal. The vessel was cooled until the module could
be safely retrieved for transport back to the NWRC.
The hydrolyzed material was transferred to a 50-mL
centrifuge tube and neutralized with PBS (pH 3). Once
the hydrolyzed sample reached a neutral pH (~8), neutral PBS was added to achieve a final inoculum volume
of 16 mL.

Mouse Model
Mice were maintained at the NWRC in cages under standard rodent housing conditions (19 to 23°C,
ambient humidity, 12:12 light:dark cycle). Mice were
monitored twice daily according to the guidelines established by the Animal Care and Use Committees at
Colorado State University and the NWRC.
One hundred twenty female C57/BL6 mice (Hilltop
Laboratory Animals, Hilltop, PA) were randomly divided into 4 groups of 30 mice each and housed in cages of
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5 mice per cage. Cages of mice were randomly assigned
to a treatment group using a random number generator. Cage numbers, except for those cages belonging
to the negative control treatment group, were blinded
to prevent prejudicial judgment of disease onset. Each
mouse was inoculated by intraperitoneal injection with
500 µL of their designated treatment material (500 µL
× 30 mice = 15 mL). One milliliter from each treatment group inoculum was retained for Western blot
analysis to identify the presence of PrPSc. Intraperitoneal inoculation was utilized for this study because
it is a less invasive surgical procedure and has fewer
complications associated with it than intracerebral inoculation. Hamir et al. (2008) explained that, whereas
the intracerebral inoculation route gives the shortest
incubation time, there are potential anesthesia-related
complications and postprocedure complications such
as intracranial hematomas and encephalitis that discourage its widespread acceptance. Three mice from
each treatment group were killed at 2 and 4 mo after
inoculation and their brain material collected for examination of PrPSc using an ELISA and Western blot
diagnostic assay. The remaining mice were monitored
for overt signs of disease. Mice still living 18 mo postinoculation, which was the set study-termination date,
were killed and analyzed for PrPSc.
To determine when mice were to be killed, several
signs of clinical disease were monitored including rough
coat, ataxia, kyphosis (hunched back), extreme lethargy, stiff tail, and collapsed abdomen. Suspect signs were
awarded 1 point and distinct signs awarded 2 points.
When a mouse attained a score of at least 6 for a period
of 3 consecutive days, or was assigned a single 1-d score
of 8 or more, the mouse was killed to prevent undue
suffering. The brain was collected from mice that died
(from any cause) or were killed and stored at −70°C
until assayed with an ELISA for the presence of PrPSc.

Diagnostic Assays
ELISA. The Bio-Rad CWD antigen test kit, ELISA (Bio-Rad Laboratories, Hercules, CA), was used to
confirm scrapie diagnosis in end-stage clinical mice. All
reagents, as well as the detailed assay procedure, are included with the purification and detection kits. Hibler
et al. (2003) provides a very thorough explanation of
the ELISA procedure that was helpful to this study.
Mouse brain tissue samples (350 mg ± 10 mg) were
deposited into grinding tubes supplied by the manufacture and homogenized (TeSeE Precess 48 Homogenizer,
Bio-Rad Laboratories) for 45 s at a speed setting of
6.5 units. Sample aliquots (250 µL) were transferred
to 2-mL polypropylene micro test tubes, 250 µL of reconstituted proteinase K solution was added to each
tube, mixed by inversion, and incubated at 37°C in a
microplate heating block for 10 min. Clarifying solution
(250 µL) was added to each tube, again mixed by inversion, and centrifuged for 7 min at 15,000 × g (20°C).
After centrifugation, the supernatant was discarded
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and the micro test tubes were dried by inversion onto
absorbent paper. Resolving buffer (25 µL) was added
to each sample and immediately incubated at 100°C for
5 min. After incubation, micro test tubes were mixed
with a vortex agitator for 5 s.
Sample diluent (125 µL) was added to each micro test
tube and mixed by pipetting the sample and diluent up
and down in the tube. A 100 µL aliquot of each diluted
sample was added to a well in a microplate (individual
wells coated with an anti-PrP monoclonal antibody),
covered with adhesive film, and incubated (37°C) for 75
min. After incubation, the adhesive film was removed,
each well washed 3 times with 800 µL of diluted wash
solution using an automatic washer (model 1575 Immunowash Microplate Washer, Bio-Rad Laboratories)
and dried by inversion onto absorbent paper. Conjugate solution (100 µL) was added to each well, then
covered with adhesive film, and incubated for 60 min
at 4°C. At the conclusion of the incubation period, the
adhesive film was removed, wells were washed 5 times
with diluted wash solution (800 µL), dried by inversion
onto absorbent paper, and 100 µL of substrate solution
was added to each well. The microplate was then incubated in the dark at ambient temperature (20°C) for 30
min. Next, 100 µL of stop solution was added to each
well, and the optical density was determined (model
550 Microplate Reader, Bio-Rad Laboratories) at 450
nm (test filter) and 620 nm (reference filter to reduce
background absorbance).
Computer software (Microplate Manager Software v.
5.2.1, Bio-Rad Laboratories) was used to analyze the
results, which included calculating the mean optical
density (OD) of the negative control and the cut-off
value for a positive sample (mean negative control OD
+ 0.210). However, K. Wilson (microbiologist/TSE testing, Veterinary Diagnostics Laboratory, Colorado State
University, Fort Collins, CO, personal communication)
explained that their laboratory has reduced error associated with performing the assay that permits using an
OD cut-off value of 0.100. As a result, the OD value of
0.100 was used as the cut-off value for this study.
Western Blot Assay. The Western blot diagnostic
assay was used to identify the presence of PrPSc in the
inocula of the different treatment groups. In addition,
it was used to confirm the ELISA results of the 2- and
4-mo killed mice (n = 24) and a sample of end-stage
clinical mice (n = 13).
Samples were thawed at ambient temperature and sodium N-lauroyl sarkosinate was added to a final concentration of 0.1% (wt/vol). Thirty-microliter aliquots were
removed and digested with 2 units Benzonase (EMD
Chemicals Inc., San Diego, CA) as per manufacturer’s
instructions. Proteinase K (PK; New England Biolabs,
Ipswich, MA) was added to a final concentration of 50
μg/mL and digested at 37°C for 60 min. The PK reactions were terminated by addition of Pefabloc [Pefabloc
SC (AEBSF), Roche Applied Science, Indianapolis,
IN] to 1 mM. Samples were prepared for electrophoresis by addition of Laemmli buffer to 1× concentration

and incubated (90°C) for 5 min. Samples were resolved
via SDS-PAGE gel (4–15% Tris HCl Ready Gel, BioRad Laboratories Inc., Hercules, CA) and transferred
to polyvinylidene fluoride membranes (Immobilon-PSQ
Transfer Membranes, Millipore Corp., Bedford, MA).
Membranes were blocked in TBS-T (25 mM Tris, 140
mM NaCl, 3 mM KCl, 0.05% Tween-20, pH 8.0) plus
5% (wt/vol) nonfat milk-powder for 40 min at ambient temperature (20°C) and exposed overnight (8 h;
4°C) to 7D9 monoclonal prion protein PrP antibody
(Abcam Inc., Cambridge, MA) in a 1:1,000-dilution of
prion protein antibody to TBS-T plus 1% milk-powder
solution. Membranes were washed 3 times (5 min each)
with TBS-T and exposed to a 1:6,666 secondary HRPantibody dilution (Calbiochem Goat Anti-Mouse H&L
Chain Specific Peroxidase Conjugate, EMD Chemicals
Inc., San Diego, CA) for 2 h at ambient temperature.
Membranes were washed as above 3 more times and
exposed to 1.2 mL of sensitivity substrate (SuperSignal
West Femto Maximum Sensitivity Substrate, Thermo
Fisher Scientific Inc., Waltham, MA) for 5 min. Membranes were photographed in a dark room (EpiChem
Darkroon, UVP BioImaging Systems, UVP Inc., Upland, CA) and processed (Labworks45, UVP Inc.). The
PVDF membranes were then stained with GelCode
Blue Stain Reagent (Thermo Fisher Scientific Inc.,
Rockford, IL) for 20 min, rinsed 10 s with 70% (vol/
vol) methanol, and dried at room temperature. This
additional step was performed to ascertain whether any
protein fragments and peptides remained after the rendering and alkaline hydrolysis treatments.

Statistical Analysis
The PROC LIFETEST procedure (SAS Inst. Inc.,
Cary, NC) was used for the survival analysis. The
Log-Rank test explored the homogeneity of the survival curves (i.e., days to death) across the 4 treatment
groups (P < 0.05). Fisher’s exact test in the PROC
FREQ procedure of SAS compared survival (i.e., delay
in days to death) across the 4 treatment groups (P <
0.05).

RESULTS AND DISCUSSION
The mouse model was initiated in December 2006.
One mouse from the rendering treatment group died
shortly after inoculation. Another mouse, this one from
the alkaline hydrolysis treatment group, died unexpectedly at 150 d and was cannibalized before it could
be removed from the cage; thus, its brain could not
be collected for analysis. However, in the days before
its death, the mouse did not display clinical signs of
scrapie.
It was hypothesized that PrPSc could be detected at
2 and or 4 mo postinoculation, which could have been
used to establish a period of time from PrPSc infection
to manifestation of disease. Initially, a 6-mo euthanasia
was scheduled also, but based on the disease-negative
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ELISA and Western blot diagnostic results from the 2and 4-mo mice (data not shown), it was decided that it
would be more valuable to leave the 6-mo mice in the
study. Studies by White et al. (2003) and Pilon et al.
(2007) identified the survival period for mice challenged
by intraperitoneal injection with mouse-adapted scrapie
that had originated from Rocky Mountain Laboratories
to be approximately 190 to 220 d.
The ELISA-based Bio-Rad CWD antigen test kit
confirmed the presence of PrPSc in mice that died of
scrapie or were killed for displaying clinical signs of
scrapie. Likewise, the ELISA confirmed that the negative control treatment group mice and alkaline hydrolysis treatment group mice, as well as the 6 rendering
treatment group mice that lived to the end of the study,
were negative for PrPSc (data not shown). The CWD
antigen test kit is not approved for detecting scrapie
prions nor is it approved for confirming prion disease
in laboratory rodents, but as discovered in this study,
the CWD antigen test kit seems capable for detecting
mouse-adapted scrapie prions.
The primary goal of preparing the rendering treatment group inoculum was to reproduce the physical
conditions of continuous-flow rendering as closely as
possible given the limitations of the laboratory setting and the small quantity of starting material. Precautions were taken to ensure that during the 45-min
cooking treatment the peak temperature of the mouse
brain homogenate did not exceed 135°C. However, considering the aforementioned limitations, it is likely that
the rendering process may have surpassed normal requirements because of the time-temperature relationship used in the rendering industry to guide commercial
rendering processes. D. Kirstein (director of technical
services, Darling International Inc., Des Moines, IA,
personal communication) explained that the temperature of the raw material does not rise significantly until
the water content is evaporated below 5%, at which
point the temperature increases expeditiously to 115
to 145°C. Rendered material exiting the cooker must
be, at a minimum, 115°C; if this temperature is not
achieved, the material is diverted from further processing and sent through the cooker again (D. Kirstein, director of technical services, Darling International Inc.,
Des Moines, IA, personal communication). Depending
on the rendering system and the raw material undergoing treatment, this process generally requires 45 to
90 min of cooking (Anderson, 2006; D. Kirstein, director of technical services, Darling International Inc.,
Des Moines, IA, personal communication). Therefore,
considering the small volume of starting material (i.e.,
one-third or ~0.110 g of the scrapie-positive mouse
brain homogenate) used for this treatment, it is likely
that the temperature of the mouse brain homogenate
reached 135°C well before the end of the cooking period. In fact, the temperature of the contents in the test
tube reached 127°C within 5 min of being suspended in
the beaker of heated shortening and was maintained at
this approximate temperature until the final minutes of
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Figure 1. Western blot of the 4 treatment group inoculums analyzed with (+) and without (–) proteinase K (PK) digestion. Note:
The circle is intended to identify the small amount of infectious prions
(PrPSc) that is believed to have survived the rendering treatment.

cooking when it was heated to its peak end-temperature
of 135°C (data not shown). Under ideal circumstances,
the excessive exposure of the mouse brain homogenate
to the simulated rendering treatment would have been
avoided by identifying an appropriate time-temperature
relationship; however, given the outcome of the mouse
model, the rendering treatment appears to have satisfied the needs of the study.
In Figure 1, the inoculum sample from the rendering
treatment group that was not exposed to PK digestion
maintained an unspecified quantity of normal prions,
PrPSc, or both after treatment, which indicated that
the rendering treatment did not cause excessive protein degradation. However, in the rendering treatment
group inoculum sample that was exposed to PK digestion, there appeared to be a low level of PrPSc that survived treatment (Figure 1). Results confirmed the suspicion that the rendering treatment was ineffective at
eliminating all PrPSc infectivity because the rendering
treatment group mice experienced a 45-d average delay
in days to death (250 vs. 205 d for the positive control
treatment group; P < 0.0001) and a 73.9% death loss
(P = 0.0094; Figure 2). Specifically, rendering delayed,
but did not stop, clinical mouse-adapted scrapie transmission.
Previous rendering studies by Taylor et al. (1995,
1997) achieved similar conclusions, in which they identified detectable infectivity in all scrapie-infected meat
and bone meal samples and in 4 of 15 BSE-infected meat
and bone meal samples after their respective rendering treatments. Infectivity was recovered in all samples
subjected to the continuous-flow rendering treatments.
Appel et al. (2001) reported that lipids protected prion
rods against peptide-bond cleavage during autoclaving,
which required increasing the autoclave temperature
for prion rod samples that contained tallow to 170°C
for 20 min to surpass the PrPSc inactivation threshold. The peak temperature of the simulated continuous cooker never exceeded 138°C. Although the mouse
brain homogenate was cooked close to this temperature
for 45 min—exceeding the necessary 20-min period; it
is plausible that the temperature inactivation threshold of PrPSc was not close enough to being breeched
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Figure 2. Survival curves for mouse treatment groups inoculated with infectious prions (PrPSc)-negative mouse brain material; PrPSc-positive
mouse brain material; rendered PrPSc-positive mouse brain material; or hydrolyzed PrPSc-positive mouse brain material.

to completely eliminate all infectivity, thereby creating
the potential for PrPSc to survive rendering and propagate the disease.
Finally, the mouse model confirmed the efficacy of
alkaline hydrolysis to inactivate PrPSc because no mice
succumbed to the disease (Figure 2). The alkaline hydrolysis process degraded all proteins, including PrPSc,
into small peptides and AA, which likely extended past
the end of the gel during protein separation (Figure 1).
This argument was further supported by the results
from staining the PVDF membranes with GelCode
Blue, which did not identify any residual protein fragments and peptides in the lanes used for separating the
alkaline hydrolysis treatment group inoculum samples
(data not shown). The alkaline hydrolysis process demonstrated its potential as a superior alternative to rendering for disposing of biological materials potentially
infected or contaminated with PrPSc (P < 0.0001).
Taylor and Woodgate (2003) reported that hot alkali
processes, like alkaline hydrolysis, are among the few
disposal methods approved by the European Union and
World Health Organization for inactivating infectious
prions.
The scrapie-positive mouse brain homogenate was
treated for 65 h, which exceeded the 6-h processing
time required by the European Commission Scientific
Steering Committee for inactivating prions by almost
11 times (Thacker, 2004). Ideally, the length of time the
mouse brain homogenate was hydrolyzed would have
been closer to 6 h, but because of factors beyond our
control and because of our interest in validating this
specific alkaline hydrolysis process in its entirety, this
was not possible. More specifically, the mouse brain
homogenate was hydrolyzed in a prototype or beta testversion of the BioMEER alkaline hydrolysis unit. Since

that time (December 2006), technological advances and
advances in cycle optimization should reduce complete
process times to between 24 to 36 h (K. Morris, owner
and chief operating officer, Hydrol-Pro Technologies
Inc., Zephyr Hills, FL, personal communication). In
addition, it should be noted that the infrastructure at
the veterinary hospital that was responsible for heating and cooling the alkaline hydrolysis unit was not
engineered to accommodate such strenuous demands,
which may have hindered the efficiency of the process.
For example, the alkaline hydrolysis unit did not reach
its peak operating temperature until 9 to 12 h after the
process was initiated.
The enhanced feed ban of the FDA is set to take
effect April 27, 2009; as a consequence, the animal rendering and beef packing industries will need to identify
alternative methods for disposing of these potentially
infectious materials. We calculated during the study
that the cost of using alkaline hydrolysis to dispose of
animal tissues and carcasses was approximately $0.26
to $0.31/kg ($0.12 to $0.14/lb). However, this cost did
not include the initial capital investment of purchasing an alkaline hydrolysis unit, as well as the cost of
building or renovating a facility to accommodate such
a unit.
Therefore, if the financial costs of this technology are
acceptable, alkaline hydrolysis should be considered by
the animal rendering and beef packing industries as an
alternative to incineration, landfill burial, and rendering for disposing of biological material potentially infected or contaminated with prion disease. In addition,
compared with incineration and landfill burial, alkaline
hydrolysis yields a sterilized proteinaceous end product
(effluent) that may have some commercial value such as
a carbon source for composting and anaerobic digestion,
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which could be sold to recuperate expenses incurred
through its operation. If the effluent were used for one
of these purposes, it may not be necessary to perform
the wastewater removal step, which could drastically
reduce the amount of time required to complete one
alkaline hydrolysis process.
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